Stock Scorecard
Stock Summary for Genfit (GNFT) - $4.24 as of 10/28/2025 12:49:45 AM EST
Total Score
13 out of 30
Safety Score
16 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GNFT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GNFT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GNFT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for GNFT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for GNFT (16 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 0 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for GNFT
Financial Details for GNFT
Company Overview |
|
|---|---|
| Ticker | GNFT |
| Company Name | Genfit |
| Country | USA |
| Description | Genfit S.A. is a biopharmaceutical company located in Loos, France, dedicated to the discovery and development of innovative therapeutics and diagnostic solutions for metabolic and liver-related diseases. With a strong emphasis on combating non-alcoholic steatohepatitis (NASH) and other liver disorders, Genfit utilizes proprietary technology platforms to advance its promising pipeline of drug candidates. The company is well-positioned in the biopharmaceutical sector, actively seeking strategic partnerships to expand its market presence and address significant unmet medical needs in this critical area of healthcare. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 11/20/2025 |
Stock Price History |
|
| Last Day Price | 4.24 |
| Price 4 Years Ago | 5.00 |
| Last Day Price Updated | 10/28/2025 12:49:45 AM EST |
| Last Day Volume | 2,941 |
| Average Daily Volume | 7,976 |
| 52-Week High | 6.03 |
| 52-Week Low | 2.55 |
| Last Price to 52 Week Low | 66.27% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.04 |
| Sector PE | 40.93 |
| 5-Year Average PE | 9.69 |
| Free Cash Flow Ratio | 1.97 |
| Industry Free Cash Flow Ratio | 14.83 |
| Sector Free Cash Flow Ratio | 29.03 |
| Current Ratio Most Recent Quarter | 3.74 |
| Total Cash Per Share | 2.15 |
| Book Value Per Share Most Recent Quarter | 1.05 |
| Price to Book Ratio | 3.24 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.16 |
| Price to Sales Ratio Twelve Trailing Months | 4.77 |
| Industry Price to Sales Ratio Twelve Trailing Months | 33.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.96 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 50,003,000 |
| Market Capitalization | 212,012,720 |
| Institutional Ownership | 0.16% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 105.22% |
| Reported EPS 12 Trailing Months | -0.91 |
| Reported EPS Past Year | -0.45 |
| Reported EPS Prior Year | 0.11 |
| Net Income Twelve Trailing Months | -35,337,000 |
| Net Income Past Year | 1,507,000 |
| Net Income Prior Year | -28,894,000 |
| Quarterly Revenue Growth YOY | -41.80% |
| 5-Year Revenue Growth | 16.79% |
| Operating Margin Twelve Trailing Months | 0.18% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 107,512,000 |
| Total Cash Past Year | 81,788,000 |
| Total Cash Prior Year | 77,789,000 |
| Net Cash Position Most Recent Quarter | 106,294,000 |
| Net Cash Position Past Year | 80,151,000 |
| Long Term Debt Past Year | 1,637,000 |
| Long Term Debt Prior Year | 57,445,000 |
| Total Debt Most Recent Quarter | 1,218,000 |
| Equity to Debt Ratio Past Year | 0.98 |
| Equity to Debt Ratio Most Recent Quarter | 0.98 |
| Total Stockholder Equity Past Year | 69,224,000 |
| Total Stockholder Equity Prior Year | 67,951,000 |
| Total Stockholder Equity Most Recent Quarter | 52,472,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 10,673,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.21 |
| Free Cash Flow Past Year | 14,570,000 |
| Free Cash Flow Prior Year | -57,917,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.08 |
| MACD Signal | 0.06 |
| 20-Day Bollinger Lower Band | 3.51 |
| 20-Day Bollinger Middle Band | 4.01 |
| 20-Day Bollinger Upper Band | 4.50 |
| Beta | 1.33 |
| RSI | 53.63 |
| 50-Day SMA | 4.01 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 3.98 |
System |
|
| Modified | 10/28/2025 12:49:46 AM EST |